MedPath

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
Registration Number
NCT05601882
Lead Sponsor
AbbVie
Brief Summary

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed.

Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment Period 1 and a 16-week treatment Period 2. Participants are randomly assigned to 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab in Period 1. There is a 30-day or 12-week follow-up visit for those on upadacitinib or dupilumab respectively, who will not enter Period 2. In Period 2, participants will receive upadacitinib Dose A or Dose B for 16 weeks, followed by a 30-day follow-up visit. Approximately 880 adolescent and adult participants ages 12 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 330 sites worldwide.

There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
920
Inclusion Criteria
  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to baseline and participant meets Hanifin and Rajka criteria.
  • Eczema area and severity index (EASI) score ≥ 16;validated Investigator´s Global Assessment for AD (vIGA-AD) score ≥ 3 and ≥ 10% Body Surface Area Involvement of Atopic Dermatitis (BSA of AD) involvement at the Baseline Visit.
  • Baseline weekly average of daily Worst Pruritus Numerical Rating Scale (WP-NRS) ≥ 4.
  • Documented history of inadequate response to previous systemic treatment defined as documented history of previous inadequate response to at least one prior systemic treatment for AD OR for whom other systemic treatments are otherwise medically inadvisable.
Exclusion Criteria
  • History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.
  • History of an organ transplant which requires continued immunosuppression.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dupilumab (Period 1)DupilumabAdult participants received a loading dose of 600 mg dupilumab by subcutaneous (SC) injection at the Baseline visit followed by 300 mg dupilumab SC every other week (EOW) until Week 16. Adolescents (12 to 17 years of age and weighing at least 40 kg) received treatment according to their body weight. Participants weighing 40 to \< 60 kg received a loading dose of 400 mg dupilumab SC at the Baseline visit followed by 200 mg SC EOW until Week 16. Those weighing 60 kg or more received a loading dose of 600 mg dupilumab SC at the Baseline visit followed by 300 mg dupilumab SC EOW until Week 16.
Upadacitinib (Period 1)UpadacitinibParticipants received 15 mg upadacitinib orally once a day (QD) up to Week 16. Starting at Week 4, participants had their dose increased to 30 mg QD if they had a \< 50% reduction from Baseline in Eczema Area and Severity Index (EASI 50) response or a \< 4-point improvement from Baseline in Worst Pruritus Numerical Rating Scale (WP-NRS; weekly average). Starting at Week 8, participants had their dose increased to 30 mg QD if they had a \< EASI 75 response.
Dupilumab -> Upadacitinib (Period 2)UpadacitinibAt Week 16, participants receiving dupilumab as per its label in Period 1 were reassigned based on their Eczema Area and Severity Index (EASI) response. Those with \< EASI 75 were offered the option to receive oral doses of upadacitinib 15 mg QD in Period 2 up to Week 32. Those with ≥ EASI 75 completed the end of study procedures. Starting at Week 20, participants with \< EASI 75 or a \< 4-point improvement from Baseline in Worst Pruritus Numerical Rating Scale (WP-NRS; weekly average) had their dose increased to 30 mg QD up to Week 32.
Upadacitinib -> Upadacitinib 30 mg (Period 2)UpadacitinibAt Week 16, participants receiving upadacitinib in Period 1 were reassigned based on their Eczema Area and Severity Index (EASI) response. Those with \< EASI 75 were allocated or continued to receive upadacitinib 30 mg QD in Period 2. Those with ≥ EASI 75 completed the end of study procedures.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16Baseline and Week 16

The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 16Baseline and Week 16

The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Percentage of Participants Achieving a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16 Among Participants With Baseline WP-NRS > 1Baseline and Week 16

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥ 4 at Week 16 Among Those With Baseline WP-NRS ≥ 4Baseline and Week 16

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Percentage of Participants Achieving a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 4 Among Participants With Baseline WP-NRS > 1Baseline and Week 4

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Percentage of Participants Achieving a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 2 Among Participants With Baseline WP-NRS > 1Baseline and Week 2

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 4Baseline and Week 4

The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Percentage of Participants Achieving a ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 2Baseline and Week 2

The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 16Baseline and Week 16

The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Trial Locations

Locations (257)

Medical Dermatology Specialists /ID# 250212

🇺🇸

Phoenix, Arizona, United States

Alliance Dermatology and Mohs Center /ID# 249671

🇺🇸

Phoenix, Arizona, United States

Clinical Trials Institute - Northwest Arkansas /ID# 249838

🇺🇸

Fayetteville, Arkansas, United States

Arkansas Research Trials /ID# 250722

🇺🇸

North Little Rock, Arkansas, United States

Joseph Raoof Md,Inc /Id# 250211

🇺🇸

Encino, California, United States

First OC Dermatology /ID# 250686

🇺🇸

Fountain Valley, California, United States

Antelope Valley Clinical Trials /ID# 249946

🇺🇸

Lancaster, California, United States

Dermatology Research Associates /ID# 249829

🇺🇸

Los Angeles, California, United States

University of California Davis Health /ID# 250044

🇺🇸

Sacramento, California, United States

Clinical Trials Research Institute /ID# 250213

🇺🇸

Thousand Oaks, California, United States

Western States Clinical Res /ID# 250274

🇺🇸

Wheat Ridge, Colorado, United States

UConn Health /ID# 253807

🇺🇸

Farmington, Connecticut, United States

Yale Center for Clinical Investigation /ID# 254791

🇺🇸

New Haven, Connecticut, United States

Clearlyderm Dermatology /ID# 250457

🇺🇸

Boca Raton, Florida, United States

Skin Care Research Boca Raton /ID# 250458

🇺🇸

Boca Raton, Florida, United States

Olympian Clinical Research /ID# 250453

🇺🇸

Clearwater, Florida, United States

Skin Care Research - Hollywood /ID# 250459

🇺🇸

Hollywood, Florida, United States

Solutions Through Adv Rch /ID# 250455

🇺🇸

Jacksonville, Florida, United States

GSI Clinical Research, LLC /ID# 250768

🇺🇸

Margate, Florida, United States

Wellness Clinical Research - Miami Lakes /ID# 250236

🇺🇸

Miami Lakes, Florida, United States

D&H National Research Centers /ID# 250734

🇺🇸

Miami, Florida, United States

Florida International Rsrch cr /ID# 249667

🇺🇸

Miami, Florida, United States

Tory P Sullivan, MD PA /ID# 251136

🇺🇸

North Miami Beach, Florida, United States

Precision Clinical Research /ID# 250990

🇺🇸

Sunrise, Florida, United States

Advanced Clinical Research Institute /ID# 250460

🇺🇸

Tampa, Florida, United States

Metabolic Research Inst /ID# 250046

🇺🇸

West Palm Beach, Florida, United States

Treasure Valley Medical Research /ID# 250727

🇺🇸

Boise, Idaho, United States

Dawes Fretzin, LLC /ID# 250276

🇺🇸

Indianapolis, Indiana, United States

Randall Dermatology of West Lafayette /ID# 250234

🇺🇸

West Lafayette, Indiana, United States

Beth Israel Deaconess Medical Center /ID# 251212

🇺🇸

Boston, Massachusetts, United States

Beacon Clinical Research, LLC /ID# 251412

🇺🇸

Quincy, Massachusetts, United States

Clarkston Dermatology /ID# 250225

🇺🇸

Clarkston, Michigan, United States

Henry Ford Medical Center - New Center One /ID# 250228

🇺🇸

Detroit, Michigan, United States

Cleaver Dermatology /ID# 250725

🇺🇸

Kirksville, Missouri, United States

MediSearch Clinical Trials /ID# 250272

🇺🇸

Saint Joseph, Missouri, United States

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 250616

🇺🇸

Lincoln, Nebraska, United States

Physician Research Collaboration, LLC /ID# 251099

🇺🇸

Lincoln, Nebraska, United States

Montefiore Medical Center - Moses Campus /ID# 251214

🇺🇸

Bronx, New York, United States

Derm of Greater Columbus /ID# 250049

🇺🇸

Bexley, Ohio, United States

Univ Hosp Cleveland /ID# 250699

🇺🇸

Cleveland, Ohio, United States

Wright State Physicians - Fairborn /ID# 254167

🇺🇸

Fairborn, Ohio, United States

Vital Prospects Clinical Research Institute, PC /ID# 249840

🇺🇸

Tulsa, Oklahoma, United States

Oregon Dermatology and Research Center /ID# 250726

🇺🇸

Portland, Oregon, United States

Oregon Medical Research Center /ID# 249666

🇺🇸

Portland, Oregon, United States

Oregon Medical Research Center /ID# 250712

🇺🇸

Portland, Oregon, United States

University of Pittsburgh MC /ID# 251208

🇺🇸

Pittsburgh, Pennsylvania, United States

Duplicate_Medical University of South Carolina /ID# 251218

🇺🇸

Charleston, South Carolina, United States

Health Concepts /ID# 250988

🇺🇸

Rapid City, South Dakota, United States

International Clinical Research - Tennessee LLC /ID# 250724

🇺🇸

Murfreesboro, Tennessee, United States

Arlington Research Center, Inc /ID# 250468

🇺🇸

Arlington, Texas, United States

Orion Clinical Research /ID# 250473

🇺🇸

Austin, Texas, United States

Bellaire Dermatology Associates /ID# 250739

🇺🇸

Bellaire, Texas, United States

Modern Research Associates, PLLC /ID# 250688

🇺🇸

Dallas, Texas, United States

Center for Clinical Studies - Houston - Northwest Freeway /ID# 250039

🇺🇸

Houston, Texas, United States

Texas Dermatology and Laser Specialists /ID# 250367

🇺🇸

San Antonio, Texas, United States

University of Utah /ID# 250042

🇺🇸

Murray, Utah, United States

University of Virginia - Dermatology /ID# 254166

🇺🇸

Charlottesville, Virginia, United States

Virginia Clinical Research, Inc. /ID# 249908

🇺🇸

Norfolk, Virginia, United States

Premier Specialist /ID# 250572

🇦🇺

Kogarah, New South Wales, Australia

Veracity Clinical Research /ID# 249943

🇦🇺

Woolloongabba, Queensland, Australia

Skin Health Institute Inc /ID# 249938

🇦🇺

Carlton, Victoria, Australia

Sinclair Dermatology - Melbourne /ID# 249937

🇦🇺

East Melbourne, Victoria, Australia

Fremantle Dermatology /ID# 249941

🇦🇺

Fremantle, Western Australia, Australia

Cliniques Universitaires UCL Saint-Luc /ID# 251403

🇧🇪

Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium

Grand Hopital de Charleroi /ID# 251401

🇧🇪

Charleroi, Hainaut, Belgium

Universitair Ziekenhuis Leuven /ID# 251399

🇧🇪

Leuven, Vlaams-Brabant, Belgium

CHU de Liege /ID# 251400

🇧🇪

Liege, Belgium

UMHAT Dr Georgi Stranski EAD /ID# 251268

🇧🇬

Pleven, Smolyan, Bulgaria

Diagnostic Consultative Center Aleksandrovska /ID# 251137

🇧🇬

Sofiya, Sofia, Bulgaria

DCC Pulmed AD /ID# 251271

🇧🇬

Plovdiv, Bulgaria

Ambulatory for Specialized Medical Care for skin and venereal diseases /ID# 251272

🇧🇬

Sofia, Bulgaria

Medical center EuroHealth /ID# 251270

🇧🇬

Sofia, Bulgaria

Military Medical Academy Multiprofile Hospital /ID# 251187

🇧🇬

Sofia, Bulgaria

Diagnostic consultative center Focus-5 /ID# 251269

🇧🇬

Sofiya, Bulgaria

Medical Center Euroderma /ID# 251267

🇧🇬

Sofiya, Bulgaria

MC Zara-Med EOOD /ID# 251135

🇧🇬

Stara Zagora, Bulgaria

Dermatology Research Institute - Blackfoot Trail /ID# 251642

🇨🇦

Calgary, Alberta, Canada

Beacon Dermatology Inc /ID# 250336

🇨🇦

Calgary, Alberta, Canada

Alberta DermaSurgery Centre /ID# 250217

🇨🇦

Edmonton, Alberta, Canada

Dr. Chih-ho Hong Medical Inc. /ID# 251643

🇨🇦

Surrey, British Columbia, Canada

Enverus Medical Research /ID# 251645

🇨🇦

Surrey, British Columbia, Canada

Wiseman Dermatology Research /ID# 250219

🇨🇦

Winnipeg, Manitoba, Canada

Brunswick Dermatology Center /ID# 250220

🇨🇦

Fredericton, New Brunswick, Canada

LEADER Research /ID# 251647

🇨🇦

Hamilton, Ontario, Canada

DermEffects /ID# 250223

🇨🇦

London, Ontario, Canada

Lynde Institute for Dermatology /ID# 251854

🇨🇦

Markham, Ontario, Canada

DermEdge Research Inc. /ID# 250216

🇨🇦

Mississauga, Ontario, Canada

SKiN Centre for Dermatology /ID# 251853

🇨🇦

Peterborough, Ontario, Canada

Toronto Dermatology Centre /ID# 252098

🇨🇦

Toronto, Ontario, Canada

Research Toronto /ID# 250222

🇨🇦

Toronto, Ontario, Canada

Private Practice - Dr. Kim Papp Clinical Research /ID# 251644

🇨🇦

Waterloo, Ontario, Canada

Centre de Recherche dermatologique du Quebec Metropolitain /ID# 250427

🇨🇦

Québec, Quebec, Canada

The First Affiliated Hospital Of Fujian Medical University /ID# 249674

🇨🇳

Fuzhou, Fujian, China

Dermatology Hospital of Southern Medical University /ID# 250121

🇨🇳

Guangzhou, Guangdong, China

Guangzhou First People's Hospital /ID# 249695

🇨🇳

Guangzhou, Guangdong, China

The Second Affiliated Hospital of Guangzhou Medical University /ID# 249694

🇨🇳

Guangzhou, Guangdong, China

The University of Hong Kong- Shenzhen Hospital /ID# 249436

🇨🇳

Shenzhen, Guangdong, China

The Second Xiangya Hospital of Central South University /ID# 249657

🇨🇳

Changsha, Guizhou, China

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 251485

🇨🇳

Wuhan, Hubei, China

The First Hospital of China Medical University /ID# 249638

🇨🇳

Shenyang, Liaoning, China

Huashan Hospital, Fudan University /ID# 250025

🇨🇳

Shanghai, Shanghai, China

Shanghai Skin Disease Hospital /ID# 249392

🇨🇳

Shanghai, Shanghai, China

Tianjin Medical University General Hospital /ID# 250246

🇨🇳

Tianjin, Tianjin, China

Hangzhou First People's Hospital /ID# 249437

🇨🇳

Hangzhou, Zhejiang, China

The second affiliated hospital of Zhejiang University school of medicine /ID# 249655

🇨🇳

Hangzhou, Zhejiang, China

Zhejiang Provincial People's Hospital /ID# 249653

🇨🇳

Hangzhou, Zhejiang, China

DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 249591

🇭🇷

Zagreb, Grad Zagreb, Croatia

Djecja bolnica Srebrnjak /ID# 249594

🇭🇷

Zagreb, Grad Zagreb, Croatia

Klinicki bolnicki centar Zagreb /ID# 249596

🇭🇷

Zagreb, Grad Zagreb, Croatia

Klinika za dječje bolesti Zagreb /ID# 249590

🇭🇷

Zagreb, Grad Zagreb, Croatia

Klinicki bolnicki centar Rijeka /ID# 249593

🇭🇷

Rijeka, Primorsko-goranska Zupanija, Croatia

Klinicki Bolnicki Centar (KBC) Split /ID# 249879

🇭🇷

Split, Splitsko-dalmatinska Zupanija, Croatia

Poliklinika Solmed /ID# 252138

🇭🇷

Grad Zagreb, Croatia

Bispebjerg and Frederiksberg Hospital /ID# 248902

🇩🇰

Copenhagen NV, Hovedstaden, Denmark

Herlev and Gentofte Hospital /ID# 248900

🇩🇰

Hellerup, Hovedstaden, Denmark

Aarhus Universitetshospital - Skejby /ID# 248899

🇩🇰

Aarhus, Midtjylland, Denmark

Roskilde Sygehus /ID# 248901

🇩🇰

Roskilde, Sjælland, Denmark

Hopital Saint Joseph /ID# 251053

🇫🇷

Marseille, Bouches-du-Rhone, France

CHU de Nantes, Hotel Dieu -HME /ID# 251347

🇫🇷

Nantes, Pays-de-la-Loire, France

HCL - Hopital Lyon Sud /ID# 251343

🇫🇷

Pierre Benite CEDEX, Rhone, France

Hôpital Saint-Louis /ID# 251052

🇫🇷

Paris, France

Universitaetsklinikum Tuebingen /ID# 249552

🇩🇪

Tubingen, Baden-Wuerttemberg, Germany

Dermatologische Gemeinschaftspraxis Mahlow /ID# 250306

🇩🇪

Blankenfelde-Mahlow, Brandenburg, Germany

Klinikum Darmstadt /ID# 251391

🇩🇪

Darmstadt, Hessen, Germany

Universitaetsklinikum Frankfurt /ID# 249544

🇩🇪

Frankfurt am Main, Hessen, Germany

Hôpital Charles-Nicolle /ID# 251055

🇫🇷

Rouen, France

CHU Toulouse - Hopital Larrey /ID# 251344

🇫🇷

Toulouse, France

Universitaetsklinikum Freiburg /ID# 249555

🇩🇪

Freiburg, Baden-Wuerttemberg, Germany

Universitaetsklinik Heidelberg /ID# 251458

🇩🇪

Heidelberg, Baden-Wuerttemberg, Germany

Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 251392

🇩🇪

Bramsche, Niedersachsen, Germany

Universitaetsklinikum Bonn /ID# 250307

🇩🇪

Bonn, Nordrhein-Westfalen, Germany

Universitaetsklinikum Muenster /ID# 249404

🇩🇪

Muenster, Nordrhein-Westfalen, Germany

Universitaetsmedizin Mainz /ID# 249549

🇩🇪

Mainz, Rheinland-Pfalz, Germany

Fachklinik Bad Bentheim /ID# 249545

🇩🇪

Bad Bentheim, Saarland, Germany

Universitaetsklinikum Leipzig /ID# 249562

🇩🇪

Leipzig, Sachsen, Germany

Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 249560

🇩🇪

Lübeck, Schleswig-Holstein, Germany

Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus /ID# 251566

🇩🇪

Bochum, Germany

Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 251844

🇩🇪

Dresden, Germany

Derma Study Center Friedrichshafen GmbH /ID# 251460

🇩🇪

Friedrichshafen, Germany

Universitaetsklinikum Hamburg-Eppendorf /ID# 249547

🇩🇪

Hamburg, Germany

Dermatologikum Hamburg /ID# 251390

🇩🇪

Hamburg, Germany

Klinikum rechts der Isar /ID# 249548

🇩🇪

Munich, Germany

401 GSNA - 401 Army General Hospital /ID# 251843

🇬🇷

Athens, Attiki, Greece

General Hospital Andreas Syggros /ID# 251842

🇬🇷

Athens, Attiki, Greece

Papageorgiou General Hospital /ID# 251840

🇬🇷

Thessaloniki, Evrytania, Greece

Bacs-Kiskun Varmegyei Oktatokorhaz /ID# 249850

🇭🇺

Kecskemet, Bacs-Kiskun, Hungary

Debreceni Egyetem-Klinikai Kozpont /ID# 249849

🇭🇺

Debrecen, Hajdu-Bihar, Hungary

Gyongyosi Bugat Pal Korhaz /ID# 251367

🇭🇺

Gyongyos, Heves, Hungary

Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 250419

🇭🇺

Pecs, Nograd, Hungary

Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 249848

🇭🇺

Kaposvár, Somogy, Hungary

Clinexpert Kft /ID# 249822

🇭🇺

Budapest, Hungary

Semmelweis Egyetem /ID# 251368

🇭🇺

Budapest, Hungary

UNO Medical Trials /ID# 249820

🇭🇺

Budapest, Hungary

DERMA-B Egeszsegugyi es Szolgaltato - Debrecen - Gyepusor Utca /ID# 249819

🇭🇺

Debrecen, Hungary

Szegedi Tudományegyetem /ID# 249818

🇭🇺

Szeged, Hungary

Allergo-Derm Bakos Kft. /ID# 249821

🇭🇺

Szolnok, Hungary

Hadassah Medical Center-Hebrew University /ID# 251576

🇮🇱

Jerusalem, Yerushalayim, Israel

Rabin Medical Center /ID# 251578

🇮🇱

Haifa, Israel

CAST - Center for Advanced Studies and Technology /ID# 251495

🇮🇹

Chieti, L Aquila, Italy

Presidio Ospedaliero San Salvatore /ID# 250127

🇮🇹

L'Aquila, L Aquila, Italy

IRCCS Istituto Clinico Humanitas /ID# 251493

🇮🇹

Rozzano, Milano, Italy

Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 250125

🇮🇹

Rome, Roma, Italy

IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 250558

🇮🇹

Rome, Roma, Italy

Policlinico Agostino Gemelli /ID# 251494

🇮🇹

Rome, Roma, Italy

ASST degli Spedali Civili di Brescia /ID# 250129

🇮🇹

Brescia, Italy

Ospedale Piero Palagi /ID# 250206

🇮🇹

Florence, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 250123

🇮🇹

Milano, Italy

Azienda Ospedaliero-Universitaria di Modena /ID# 250128

🇮🇹

Modena, Italy

Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 251572

🇮🇹

Perugia, Italy

Azienda Ospedaliero Universitaria Pisana /ID# 250124

🇮🇹

Pisa, Italy

Medical Corporation Kojinkai Sapporo Skin Clinic /ID# 252549

🇯🇵

Sapporo-shi, Hokkaido, Japan

Medical corporation Kojunkai Kosugi Dermatology Clinic /ID# 252554

🇯🇵

Kawasaki-shi, Kanagawa, Japan

National Hospital Organization Sagamihara National Hospital /ID# 254518

🇯🇵

Sagamihara-shi, Kanagawa, Japan

Queen's Square Medical Center, Dermatology and Allergology /ID# 252551

🇯🇵

Yokohama-shi, Kanagawa, Japan

Osaka Habikino Medical Center /ID# 252550

🇯🇵

Habikino-shi, Osaka, Japan

Dermatology and Ophthalmology Kume Clinic /ID# 254570

🇯🇵

Sakai-shi, Osaka, Japan

Naoko Dermatology Clinic /ID# 254571

🇯🇵

Setagaya-ku, Tokyo, Japan

Pusan National University Hospital /ID# 249852

🇰🇷

Busan, Busan Gwang Yeogsi, Korea, Republic of

Kyungpook National University Hospital /ID# 249855

🇰🇷

중구, Daegu Gwang Yeogsi, Korea, Republic of

Korea University Ansan Hospital /ID# 249814

🇰🇷

Ansan-si, Gyeonggido, Korea, Republic of

Soon Chun Hyang University Hospital Bucheon /ID# 249812

🇰🇷

Bucheon-si, Gyeonggido, Korea, Republic of

Chungang University Hospital /ID# 251490

🇰🇷

Dongjak-gu, Gyeonggido, Korea, Republic of

Ajou University Hospital /ID# 251491

🇰🇷

Suwon-si, Gyeonggido, Korea, Republic of

Seoul National University Hospital /ID# 251492

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Konkuk University Medical Center /ID# 249811

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Centro de Dermatologia de Monterrey /ID# 249126

🇲🇽

Monterrey, Baja California, Mexico

Eukarya PharmaSite, SC /ID# 249702

🇲🇽

Monterrey, Nuevo Leon, Mexico

Cryptex Investigacion Clinica S.A de C.V /ID# 249994

🇲🇽

Mexico City, Mexico

Clinical Research Institute SC /ID# 249647

🇲🇽

Tlalnepantla de Baz, Mexico

Arké Estudios Clinicos Veracruz /ID# 250147

🇲🇽

Veracruz, Mexico

Bravis Ziekenhuis /ID# 251395

🇳🇱

Bergen op Zoom, Noord-Brabant, Netherlands

Amsterdam UMC, locatie AMC /ID# 251397

🇳🇱

Amsterdam, Noord-Holland, Netherlands

MICS Centrum Medyczne Torun /ID# 251433

🇵🇱

Torun, Kujawsko-pomorskie, Poland

Dermed Centrum Medyczne Sp. z o.o /ID# 251429

🇵🇱

Lodz, Lodzkie, Poland

Lidia Rajzer - Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny /ID# 252082

🇵🇱

Cracow, Malopolskie, Poland

Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. /ID# 251437

🇵🇱

Krakow, Malopolskie, Poland

Royalderm Agnieszka Nawrocka /ID# 251432

🇵🇱

Warsaw, Mazowieckie, Poland

Klinika Ambroziak Sp. z o.o. /ID# 249406

🇵🇱

Warszawa, Mazowieckie, Poland

Bodyclinic Sp. z o.o. sp.k. /ID# 249599

🇵🇱

Warszawa, Mazowieckie, Poland

Zespol Naukowo-Leczniczy Iwolang Dermatologiczne Centrum Uzdrowiskowe Sp. z o.o /ID# 249598

🇵🇱

Iwonicz-Zdrój, Podkarpackie, Poland

INTER CLINIC Piotr Adrian Klimiuk /ID# 251430

🇵🇱

Bialystok, Podlaskie, Poland

Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 251431

🇵🇱

Gdansk, Pomorskie, Poland

Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 251438

🇵🇱

Elblag, Warminsko-mazurskie, Poland

Solumed Centrum Medyczne /ID# 249641

🇵🇱

Poznan, Wielkopolskie, Poland

Centrum Medyczne ALL-MED Badania Kliniczne /ID# 249630

🇵🇱

Cracow, Poland

Centro Hospitalar Do Alto Ave - Hospital Senhora Da Oliveira /ID# 249196

🇵🇹

Guimarães, Braga, Portugal

Hospital CUF Descobertas /ID# 249193

🇵🇹

Lisboa, Regiao Autonoma Da Madeira, Portugal

Centro Hospitalar Universitario do Porto, EPE - Hospital Santo Antonio /ID# 249191

🇵🇹

Porto, Regiao Autonoma Da Madeira, Portugal

Hospital Garcia de Orta /ID# 251455

🇵🇹

Almada, Setubal, Portugal

2CA-Braga, Hospital de Braga /ID# 250480

🇵🇹

Braga, Portugal

Unidade Local de Saude da Regiao de Leiria, EPE /ID# 249194

🇵🇹

Leiria, Portugal

Centro Hospitalar de Lisboa Central /ID# 249195

🇵🇹

Lisbon, Portugal

Unidade Local de Saúde de Matosinhos, EPE /ID# 249197

🇵🇹

Matosinhos, Portugal

Centro Hospitalar Universitario de Sao Joao, EPE /ID# 249192

🇵🇹

Porto, Portugal

Dr. Samuel Sanchez PSC /ID# 250389

🇵🇷

Caguas, Puerto Rico

Alma M. Cruz Santana, MD-Private practice /ID# 250393

🇵🇷

Carolina, Puerto Rico

Clinical Research Puerto Rico /ID# 250394

🇵🇷

San Juan, Puerto Rico

GCM Medical Group PSC /ID# 250391

🇵🇷

San Juan, Puerto Rico

Bio Terra Med SRL /ID# 249624

🇷🇴

Bucharest, Bucuresti, Romania

Private Practice - Dr. Orasan Remus /ID# 249625

🇷🇴

Cluj Napoca, Cluj, Romania

Derma therapy spol /ID# 249783

🇸🇰

Bratislava, Bratislavsky Kraj, Slovakia

Poliklinika Bezrucova (Cliniq s.r.o.) /ID# 249746

🇸🇰

Bratislava, Slovakia

BeneDerma s.r.o. /ID# 251791

🇸🇰

Bratislava, Slovakia

University of Pretoria /ID# 250208

🇿🇦

Pretoria, Gauteng, South Africa

About Allergy /ID# 249697

🇿🇦

Pretoria, Gauteng, South Africa

Highway Medical Centre /ID# 250103

🇿🇦

Durban, Kwazulu-Natal, South Africa

Spoke Research Inc /ID# 250091

🇿🇦

CAPE TOWN Milnerton, Western Cape, South Africa

Allergy & Immunology (AIU) /ID# 249619

🇿🇦

Cape Town, Western Cape, South Africa

Hospital Universitario Germans Trias i Pujol /ID# 251523

🇪🇸

Badalona, Barcelona, Spain

Hospital Sant Joan de Deu /ID# 249602

🇪🇸

Esplugues de Llobregat, Barcelona, Spain

Hospital Universitario Basurto /ID# 249784

🇪🇸

Bilbao, Vizcaya, Spain

Hospital General Universitario de Alicante Doctor Balmis /ID# 251517

🇪🇸

Alicante, Spain

Hospital Universitario Virgen de las Nieves /ID# 249785

🇪🇸

Granada, Spain

Hospital Universitario La Paz /ID# 251518

🇪🇸

Madrid, Spain

Hospital Universitario Virgen Macarena /ID# 249603

🇪🇸

Sevilla, Spain

Hospital Universitario y Politecnico La Fe /ID# 251524

🇪🇸

Valencia, Spain

Skane University hospital /ID# 250332

🇸🇪

Malmo, Skane Lan, Sweden

Karolinska University Hospital Solna /ID# 250328

🇸🇪

Solna, Stockholms Lan, Sweden

Norrlands University hospital /ID# 250329

🇸🇪

Umea, Vasterbottens Lan, Sweden

Malarsjukhuset /ID# 251908

🇸🇪

Eskilstuna, Sweden

Kantonsspital St. Gallen /ID# 250606

🇨🇭

St. Gallen, Sankt Gallen, Switzerland

Inselspital, Universitaetsspital Bern /ID# 250577

🇨🇭

Bern, Switzerland

Kaohsiung Chang Gung Memorial Hospital /ID# 249260

🇨🇳

Kaohsiung City, Kaohsiung, Taiwan

Taichung Veterans General Hospital /ID# 249261

🇨🇳

Taichung, Keelung, Taiwan

National Taiwan University Hospital /ID# 249258

🇨🇳

Taipei City, Taipei, Taiwan

National Taiwan University Hospital - Hsinchu branch /ID# 249265

🇨🇳

Hsinchu City, Taiwan

Taipei Medical University Shuang Ho Hospital /ID# 249256

🇨🇳

New Taipei City, Taiwan

Mackay Memorial Hospital /ID# 249259

🇨🇳

Taipei City, Taiwan

Taipei Veterans General Hosp /ID# 249263

🇨🇳

Taipei, Taiwan

Taipei Municipal Wan Fang Hospital /ID# 251500

🇨🇳

Taipei, Taiwan

Linkou Chang Gung Memorial Hospital /ID# 249257

🇨🇳

Taoyuan City, Taiwan

Gaziantep Universitesi /ID# 249868

🇹🇷

Gaziantep, Adana, Turkey

Ankara City Hospital /ID# 249870

🇹🇷

Ankara, Turkey

Akdeniz Universitesi Tip Fakul /ID# 249866

🇹🇷

Antalya, Turkey

Uludag University Medical Faculty /ID# 249864

🇹🇷

Bursa, Turkey

Erciyes University Medical Faculty /ID# 249863

🇹🇷

Kayseri, Turkey

Ondokuz Mayis Universitesi /ID# 249865

🇹🇷

Samsun, Turkey

© Copyright 2025. All Rights Reserved by MedPath